Table 2.
Combination study of compound 5 and 17 with machaeriol C by checkerboard* assay against MRSA.
| Compound | MRSA (ATCC 1708) MIC (μg/mL) |
Concentration (μg/mL) |
Combination Effect MIC (μg/mL) |
|---|---|---|---|
| 5 | 1.25 | 5 + MC @ 0.625 | MIC of 5 @ 0.312 (^4X) |
| Machaeriol C (MC) | 1.25 | MC + 5 @ 0.625 | MIC of MC @ 0.625 (^2X) (FIC 0.75) |
| 17 | 0.625 | 17 + MC @ 0.156 | MIC of 17 @ 0.156 (^4X) |
| 17 + MC @ 0.312 | MIC of 17 @ 0.312 (^2X) | ||
| Machaeriol C (MC) | 1.25 | MC + 17 @ 0.156 | MIC of MC @ 0.625 (^2X) |
| MC + 17 @ 0.312 | MIC of MC @ 0.312 (^4X) (FIC 0.50) | ||
| Ancomycin | 1.00 | - | - |
| - | - | 5 + Vancomyci | No effect (FIC > 1) |
| - | - | 17 + Vancomycin | No effect (FIC > 1) |
* Checkerboard assays of compound 5 and 17 were run separately at two different dates, each in triplicate. In addition, 17 was run two times (^2X: two-fold reduction in MIC; ^4X: four-fold reduction in MIC; FIC: fractional inhibitory concentrations).